Dr RR Baliga's "Got Knowledge Doc" Podkast

🌍 Cardiovascular disease (CVD) remains the leading global killer. 📊 In 2023, CVD caused 19.2M deaths and 437M DALYs ( JACC ). 🔮 By 2050, projections show 35.6M deaths and 1.14B cases ( EJPC ) — driven by ageing, hypertension, obesity, and dysglycemia.   ⚠️ While age-standardized mortality is projected to fall 30% , the absolute burden will nearly double , with the steepest rise in South & East...

🌍 50,000 years of India's evolutionary history 🇮🇳🧬 New genomic research sequencing 2,762 individuals across India reveals: ✨ A major migration out of Africa ~50,000 years ago 🦴 1–2% ancestry from Neanderthals & Denisovans 🔗 Strong founder effects & endogamy raising recessive disease risk 🧩 >160,000 novel variants unique to India, some linked to immunity & drug response   These findings highl...

💉 RSV Vaccines: From NEJM to JAMA, Lungs to Heart! ❤️🫁   Evidence is converging— NEJM , DAN-RSV Trial 🇩🇰 , CDC real-world study 🇺🇸 , and a powerful JAMA editorial 📰—that bivalent RSV vaccines protect not just against severe respiratory illness but may also lower cardiorespiratory hospitalizations in older adults 👵👴. A new frontier where infection prevention meets cardiovascular health 🌍✨ Ku...

🔍 William of Ockham (c.1287–1347), the Franciscan friar & philosopher, gave us Occam's Razor ✂️ —the call to seek the simplest, most evidence-based explanations. His logic, nominalism & challenge to authority echo in today's science, ethics & healthcare 🩺📜. A reminder for providers: clarity, parsimony & humility in reasoning can guide better care. 🌍✨ #Wisdom #Healthcare

🦠💉 Five landmark studies shed new light on influenza vaccines! 🇪🇸 GALFLU (Spain, NEJM) : High-dose vaccine cut influenza/pneumonia hospitalizations. 🇩🇰 DANFLU-2 (Denmark, NEJM & JAMA) : Neutral primary outcome but signals for fewer CV & HF hospitalizations. 🇨🇳 PANDA II (China, Lancet) : In-hospital vaccination lowered mortality & readmissions in acute HF. 📊 JAMA Editorial by Robert Califf : Cal...

🌟 New insights into extreme longevity ! 🌟 Our latest read on the multiomics blueprint of a 117-year-old supercentenarian reveals how genetics 🧬, metabolism ⚡, microbiome 🌱, and epigenetics 🕰️ can decouple aging from disease. 📊 Findings: Ultra-short telomeres but no cancer 📉 Protective genetic variants and robust mitochondria 💪 Efficient lipid metabolism (high HDL, low triglycerides) 💧 Low...

🚨 New Evidence Alert 🚨 The SWEDEPAD 1 & 2 trials + a powerful Lancet commentary have reshaped how we view paclitaxel-coated devices in peripheral artery disease.   👉 No benefit for amputation or quality of life . 👉 A concerning signal for higher 5-year mortality in claudication. 👉 Registry-based RCTs prove invaluable for real-world insights.   ⚖️ Message: Harm may outweigh benefit — time to r...

🚨 Breakthrough in Huntington's Disease 🧬🧠✨   Exciting results from the pivotal Phase I/II AMT-130 gene therapy trial show a 75% slowing of disease progression at 36 months compared to controls. Key functional and cognitive endpoints (cUHDRS, TFC, SWRT, SDMT) also demonstrated significant benefit, alongside biomarker reduction in CSF neurofilament light chain 📊🔑.   💉 Delivered via precision...

🚨 GLP-1 Medicines: Beyond Diabetes! 💉🧠💪 From weight loss to brain health, the future of GLP-1 therapies is unfolding fast! 🌍✨   New agents like retatrutide and MariTide are redefining outcomes in obesity, neurodegeneration, and substance use disorders . 🔬 Oral options, muscle-sparing combos, and triple agonists are here.   🧪 Dive into 15+ FAQs from the latest JAMA 2025 Perspective — format...

💡 Fresh insights from a randomized crossover trial in people with Type 2 Diabetes (T2D)! 🍽️🚶‍♂️   High-fat 🥑 and high-carb 🍞 meals, with or without a light post-meal walk, showed no adverse effects on cardiac autonomic modulation or ECG intervals. ✅ Heart rate variability held steady, and walking even gave a gentle boost without risk.   🫀 Key Takeaway : Flexible dietary choices and safe post...

🚨 New Insights in Dilated Cardiomyopathy (DCM)! 🫀 Fibroblasts aren't just bystanders — they're mechanical rheostats shaping disease severity. 🧬 This groundbreaking study shows that blocking p38 signaling halts fibrosis, boosts contractility, and may redefine how we treat DCM. 💥 🧠 Think beyond myocytes. Think collective cell behavior . 🧪 Read the full paper in Science : "Preventing Hypocontra...

🚨 New frontier in #NeuroRehab & #BioelectronicMedicine! Just explored two groundbreaking studies on autonomic dysreflexia and implantable neurostimulation in spinal cord injury (SCI) 🧠💥 ⚡ One reveals the neuronal circuitry driving dangerous BP spikes 🔌 The other shows how epidural stimulation at T11–L1 can restore BP within 2 minutes 💡 Together, they mark a paradigm shift—from managing sympt...

🫀 NEWTON-CABG Trial : Can intensive LDL-C lowering prevent vein graft failure after CABG? 💉 Evolocumab slashed LDL-C by ~50%, but did  not improve SVG patency at 2 years. Why? Timing is everything. 🧠 Early SVG failure = thrombosis & hyperplasia—not classic atherosclerosis. LDL-C ≠ magic bullet here. #Cardiology #CABG #LDL #PCSK9 #Evolocumab #CardioTrials #Lipids #HeartHealth #GraftPatency #Clin...

🧠💤 Why do we sleep? A groundbreaking Neuron article explores this timeless question through a bold new lens: 🛌 The Motor Theory & Catecholamine Hypothesis of Sleep.   Instead of a single "sleep center," 🧬 sleep emerges from distributed motor control circuits regulating both somatic & autonomic activity. And the "why"? 😴 Suppressing dopamine, noradrenaline & adrenaline may be key to healing ou...

🚨 New insights from the Lancet ! 🚑 In the OPTION–STEMI trial, immediate multivessel PCI during the index procedure failed to show non-inferiority compared to staged revascularisation in STEMI patients with multivessel disease.   🧠 Key takeaway? Timing matters. ⚠️ Higher risk in those with heart failure (Killip II/III) 💡 Safer strategy: staged PCI for high-risk patients   📊 Fractional flow res...

✨ St. Thomas Aquinas (1225–1274) — Dominican friar, philosopher & theologian — is among the most influential thinkers in Western tradition. 📖 His Summa Theologica shaped Catholic theology, blending Aristotle's philosophy with Christian faith. 🕊️ Known as the Doctor Angelicus , he championed faith & reason, natural law ⚖️, and virtue ethics 💡— principles that still guide philosophy, theology, an...

🚨 New Podcast Drop! 🎙️ "VICTOR, Vericiguat, and Victory?" unpacks the Lancet trilogy — the VICTOR trial, pooled analysis, and expert commentary 🧠📊💊. We explore Vericiguat's evolving role across the heart failure spectrum 💓📉 and what it means for clinical care in HFrEF patients.   📚 Trials discussed: VICTOR, VICTORIA 🎧 Tune in for insights on risk-based treatment effects, NT-proBNP threshol...

🎭 Just explored a landmark Nature Medicine review on how the arts can prevent noncommunicable diseases (NCDs) across 27 countries! 🎨 From dance and drama to gardening and storytelling, arts-based interventions improved physical activity, diet, and mental well-being—especially in underserved communities. 📊 A must-read for anyone interested in health equity , cultural relevance , and community-le...

💊 Orforglipron : A new era in obesity treatment?   In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️   🔥 Nearly 1 in 5 patients lost ≥20% body weight 💡 A promising alternative to injectable therapies   Accessible. Effective. Oral. 👉 A game-chan...

🚨 New Podcast Drop! 🎙️ "Myosin, Metrics & Momentum 🧬📈🫀" dives into 3 landmark NEJM articles on Aficamten vs Mavacamten in hypertrophic cardiomyopathy.   We decode: 🔹 MAPLE-HCM (obstructive HCM) 🔹 ODYSSEY-HCM (nonobstructive HCM) 🔹 Expert editorial insights on PROs, EF, & trial design   🎯 Learn what matters: peak VO₂ vs PROs, safety signals, and the road ahead in precision cardiomyopathy ca...

  💊 New Hope in a Pill for Obesity? The 71-week OASIS 4 trial shows that oral semaglutide 25 mg led to a 13.6% weight loss , improved physical function, and reversed prediabetes in 71% of cases—all without injections. 📉 Effective. 🧬 Metabolically beneficial. 📦 Orally delivered.   #ObesityCare #GLP1 #Semaglutide #NEJM #DigitalHealth #Cardiometabolic

☀️ Walking on Sunshine? Rethinking Our Relationship with the Sun! 🧴🧬 New research—spotlighted in The Economist (Sep 20, 2025)—challenges old assumptions: Could moderate sun exposure reduce cardiovascular mortality? ❤️📉 From nitric oxide to vitamin D, this FAQ explores the science, nuance, and shifting global guidelines. Let's talk melanin, mortality, and medicine! 🌍💡 #Sunlight #Cardiovascular...

🚨 Cardiogenic Shock—A Decade Later The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone. 📉 Mortality: 52.5% vs 68.8% (HR 0.70) 🛠️ Despite higher adverse events, the survival benefit endured a full decade . 📊 This changes how we think about long-term outcomes in mechanical support...

🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬   📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare's first autopsy to myosin inhibitors , AI diagnostics , and gene therapy .   💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advances—all distilled into one must-read.  ...

🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk , monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥   ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions   🔬 APOC3 inhibition emerges as a game-changer in lipidolo...